China Resources Pharmaceutical Group Ltd (3320)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:China Resources Pharmaceutical Group Ltd (3320) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014296
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:香港
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
China Resources Pharmaceutical Group Ltd (CR Pharma), a subsidiary of China Resources (Holdings) Co Ltd is a pharmaceutical company that offers nutritional supplements. The company offers research and development, manufacture, and distribution of whole drug products. Its products comprise chemical medicines, TCMs, biologics, and health food and traditional Chinese medicine, and nutritional products. CR Pharma offers products in forms of oral solid dosage, large infusion bags, powder vials, oral liquid dosage, injections, and topical preparations. The company markets its products through logistics, wholesale, retail and supply chain services in different provinces across China. CR Pharma is headquartered in Hong Kong.

China Resources Pharmaceutical Group Ltd (3320) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
China Resources Pharmaceutical Group Ltd, Medical Devices Deals, 2011 to YTD 2017 9
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
China Resources Pharmaceutical Enters into Agreement with Fujifilm 12
China Resources Pharmaceutical Enters into Co-Development Agreement with WuXi AppTec 13
Pfizer and CR Saike Pharma Enter into Distribution Agreement 14
China Resources Zizhu Enters into Agreement with Uni-Bio Science 15
China Resources Zizhu Pharma Enters into Distribution Agreement with Uni-Bio Science 16
China Resources Pharma and National Center for Nanoscience and Technology Enter into Agreement 17
China Resources Sanjiu Medical To Form Joint Venture 18
Licensing Agreements 19
Basilea Pharma Enters into Licensing Agreement with Shenzhen Gosun Pharma 19
Equity Offering 20
China Resources Pharma Raises USD1.8 Million in IPO 20
Acquisition 22
China Resources Sanjiu Medical Acquires China Shenghuo Pharma for USD282 Million 22
China Resources Sanjiu Medical to Acquire Kunming Shenghuo Pharmaceutical for USD283 Million 23
China Resources Double Crane Pharma to Acquire China Resources Saike Pharma for USD578.6 Million 24
The Special Committee Of China Shenghuo Pharma Approves Going Private Proposal From Lan’s Int’l Medicine Investment 25
China Resources Sanjiu Medical Acquires 97.18% Stake In Guilin Tianhe Pharma For US$94 Million 26
China Resources Sanjiu Medical To Acquire Guangdong Shunfeng Pharma For US$95 Million 27
China Resources Sanjiu Medical Plans To Acquire Four Pharma Companies For US$63.26 Million 28
China Resources Pharmaceutical Group Ltd – Key Competitors 29
China Resources Pharmaceutical Group Ltd – Key Employees 30
China Resources Pharmaceutical Group Ltd – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 33
Financial Announcements 33
Aug 24, 2017: China Resources Pharmaceutical Group: Interim Results Announcement For The Six Months Ended 30 June 2017 33
Corporate Communications 37
Aug 07, 2017: China Resources Pharmaceutical: Appointment of Independent Non-executive Director 37
Legal and Regulatory 38
Aug 02, 2016: China Resources Sanjiu’s “Er Xie Ting Ke Li” Listed as Protected TCM 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2015 2
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
China Resources Pharmaceutical Group Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
China Resources Pharmaceutical Group Ltd, Medical Devices Deals, 2011 to YTD 2017 9
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
China Resources Pharmaceutical Enters into Agreement with Fujifilm 12
China Resources Pharmaceutical Enters into Co-Development Agreement with WuXi AppTec 13
Pfizer and CR Saike Pharma Enter into Distribution Agreement 14
China Resources Zizhu Enters into Agreement with Uni-Bio Science 15
China Resources Zizhu Pharma Enters into Distribution Agreement with Uni-Bio Science 16
China Resources Pharma and National Center for Nanoscience and Technology Enter into Agreement 17
China Resources Sanjiu Medical To Form Joint Venture 18
Basilea Pharma Enters into Licensing Agreement with Shenzhen Gosun Pharma 19
China Resources Pharma Raises USD1.8 Million in IPO 20
China Resources Sanjiu Medical Acquires China Shenghuo Pharma for USD282 Million 22
China Resources Sanjiu Medical to Acquire Kunming Shenghuo Pharmaceutical for USD283 Million 23
China Resources Double Crane Pharma to Acquire China Resources Saike Pharma for USD578.6 Million 24
The Special Committee Of China Shenghuo Pharma Approves Going Private Proposal From Lan's Int'l Medicine Investment 25
China Resources Sanjiu Medical Acquires 97.18% Stake In Guilin Tianhe Pharma For US$94 Million 26
China Resources Sanjiu Medical To Acquire Guangdong Shunfeng Pharma For US$95 Million 27
China Resources Sanjiu Medical Plans To Acquire Four Pharma Companies For US$63.26 Million 28
China Resources Pharmaceutical Group Ltd, Key Competitors 29
China Resources Pharmaceutical Group Ltd, Key Employees 30
China Resources Pharmaceutical Group Ltd, Other Locations 31
China Resources Pharmaceutical Group Ltd, Subsidiaries 31

★海外企業調査レポート[China Resources Pharmaceutical Group Ltd (3320)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Odakyu Electric Railway Co., Ltd. (9007):企業の財務・戦略的SWOT分析
    Odakyu Electric Railway Co., Ltd. (9007) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • CeoTronics AG (CEK):企業の財務・戦略的SWOT分析
    CeoTronics AG (CEK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Bloomberg L.P.:戦略・SWOT・企業財務分析
    Bloomberg L.P. - Strategy, SWOT and Corporate Finance Report Summary Bloomberg L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Cedars-Sinai Medical Center:企業のM&A・事業提携・投資動向
    Cedars-Sinai Medical Center - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Cedars-Sinai Medical Center Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Activision Blizzard Inc (ATVI):企業の財務・戦略的SWOT分析
    Activision Blizzard Inc (ATVI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Success Universe Group Limited:企業の戦略・SWOT・財務分析
    Success Universe Group Limited - Strategy, SWOT and Corporate Finance Report Summary Success Universe Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Wright Medical Group NV (WMGI)-医療機器分野:企業M&A・提携分析
    Summary Wright Medical Group NV (Wright) is an international orthopedic medical device company with focus on extremity and biologic solutions. The company designs, manufactures and markets reconstructive joint devices including extremity implants for the shoulder, elbow, foot, ankle and hand; foot a …
  • Bharat Heavy Electricals Limited (BHEL):企業の戦略・SWOT・財務情報
    Bharat Heavy Electricals Limited (BHEL) - Strategy, SWOT and Corporate Finance Report Summary Bharat Heavy Electricals Limited (BHEL) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Canfor Corporation (CFP):企業の財務・戦略的SWOT分析
    Canfor Corporation (CFP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Rubius Therapeutics Inc (RUBY):製薬・医療:M&Aディール及び事業提携情報
    Summary Rubius Therapeutics Inc (Rubius Therapeutics) is a biotechnology company that focuses on the development of medicines for the treatment of rare diseases, cancer and autoimmune diseases. The company through its rubius erythrocyte design (RED) platform engineer and culture Red Cell Therapeutic …
  • Cabot Oil & Gas Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Cabot Oil & Gas Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Cabot Oil & Gas Corp (Cabot) is an independent oil and gas company, which develops, and explores for oil and gas properties primarily in the continental US. It focuses on developing natural gas …
  • BioElectron Technology Corp-製薬・医療分野:企業M&A・提携分析
    Summary BioElectron Technology Corp(BioElectron) formerly known as Edison Pharmaceuticals Inc, discovers and develops shared (redox) disease drugs. The company’s pipeline products comprise EPI-743, a drug candidate for inherited mitochondrial diseases and EPI-589 drug candidate entering phase 1 clin …
  • Heineken NV:企業の戦略・SWOT・財務分析
    Heineken NV - Strategy, SWOT and Corporate Finance Report Summary Heineken NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Pioneer Corporation (6773):企業の財務・戦略的SWOT分析
    Pioneer Corporation (6773) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Harbin Electric International Co Ltd:企業の戦略的SWOT分析
    Harbin Electric International Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Prexton Therapeutics SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Prexton Therapeutics SA (Prexton) is a developer of drugs for Parkinson’s disease and other brain disorders. The company designs and develops mGluR4 positive allosteric modulator compounds for the treatment for Parkinson’s disease. It also develops positive allosteric modulators, or PAMs to …
  • Viacom, Inc.:企業の戦略・SWOT・財務情報
    Viacom, Inc. - Strategy, SWOT and Corporate Finance Report Summary Viacom, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Martinrea International Inc:企業の戦略・SWOT・財務情報
    Martinrea International Inc - Strategy, SWOT and Corporate Finance Report Summary Martinrea International Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • MEDITE Cancer Diagnostics Inc (MDIT):企業の財務・戦略的SWOT分析
    MEDITE Cancer Diagnostics Inc (MDIT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Arista Investors Corp:企業の戦略・SWOT・財務情報
    Arista Investors Corp - Strategy, SWOT and Corporate Finance Report Summary Arista Investors Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆